BTC Capital Management Inc. Buys 4,977 Shares of Merck & Co., Inc. (NYSE:MRK)

BTC Capital Management Inc. grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 7.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,500 shares of the company’s stock after buying an additional 4,977 shares during the period. BTC Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $6,099,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in MRK. Ceredex Value Advisors LLC purchased a new position in shares of Merck & Co., Inc. in the second quarter valued at $102,394,000. Personal Capital Advisors Corp grew its holdings in shares of Merck & Co., Inc. by 11.9% in the second quarter. Personal Capital Advisors Corp now owns 75,736 shares of the company’s stock valued at $5,857,000 after purchasing an additional 8,048 shares in the last quarter. Capital Asset Advisory Services LLC grew its holdings in shares of Merck & Co., Inc. by 15.2% in the first quarter. Capital Asset Advisory Services LLC now owns 8,079 shares of the company’s stock valued at $629,000 after purchasing an additional 1,066 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Merck & Co., Inc. by 18.1% in the second quarter. Janney Montgomery Scott LLC now owns 1,372,241 shares of the company’s stock valued at $106,115,000 after purchasing an additional 209,990 shares in the last quarter. Finally, First PREMIER Bank grew its holdings in shares of Merck & Co., Inc. by 5.2% in the second quarter. First PREMIER Bank now owns 27,864 shares of the company’s stock valued at $2,154,000 after purchasing an additional 1,389 shares in the last quarter. Hedge funds and other institutional investors own 73.18% of the company’s stock.

Shares of MRK opened at $79.83 on Friday. The firm has a market capitalization of $201.91 billion, a P/E ratio of 19.47, a P/E/G ratio of 2.10 and a beta of 0.43. Merck & Co., Inc. has a 12-month low of $65.25 and a 12-month high of $92.64. The company has a current ratio of 1.32, a quick ratio of 1.05 and a debt-to-equity ratio of 0.94. The firm has a fifty day moving average price of $83.27 and a 200-day moving average price of $80.42.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, July 31st. The company reported $1.37 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.23. The firm had revenue of $10.87 billion during the quarter, compared to analyst estimates of $10.52 billion. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 52.94%. The business’s revenue was down 7.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.30 earnings per share. Analysts predict that Merck & Co., Inc. will post 5.68 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were paid a dividend of $0.61 per share. This represents a $2.44 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date of this dividend was Monday, September 14th. Merck & Co., Inc.’s dividend payout ratio is currently 47.01%.

A number of research analysts recently weighed in on MRK shares. ValuEngine lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Thursday, October 1st. Morgan Stanley reaffirmed a “buy” rating and set a $89.00 price objective on shares of Merck & Co., Inc. in a research note on Tuesday, June 23rd. SVB Leerink lifted their price objective on shares of Merck & Co., Inc. from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 25th. Mizuho reaffirmed a “buy” rating on shares of Merck & Co., Inc. in a research note on Tuesday, September 22nd. Finally, Royal Bank of Canada reaffirmed a “hold” rating on shares of Merck & Co., Inc. in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $95.08.

In related news, EVP Frank Clyburn sold 18,876 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $81.55, for a total value of $1,539,337.80. Following the completion of the sale, the executive vice president now directly owns 99,639 shares in the company, valued at $8,125,560.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sanat Chattopadhyay sold 10,380 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $83.01, for a total value of $861,643.80. The disclosure for this sale can be found here. Insiders have sold 280,529 shares of company stock valued at $22,761,633 over the last three months. Insiders own 0.28% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: How does a reverse stock split work?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.